Pfizer posts Phase 3 data for Lyme vaccine candidate LB6V at IDWeek 2026

Bitget2026/10/14 10:45

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Pfizer flagged Phase 3 results for its LB6V Lyme disease vaccine candidate, with IDWeek 2026 presentations scheduled Oct. 22.
The readout supported the shot’s ability to protect against Lyme disease, strengthening its case as a potential new commercial vaccine entrant.
Regulatory momentum advanced in Europe, with the EMA starting its review of the marketing application in August 2026.
Separate IDWeek 2026 presentations will cover Phase 2 data for a 25-valent pediatric pneumococcal candidate, with results previously announced in May 2026.
Pfizer also highlighted Phase 3 findings for an LP.8.1-adapted Comirnaty formulation in at-risk children, supporting its updated COVID-19 franchise.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261014474581) on October 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Pfizer posts Phase 3 data for Lyme vaccine candidate LB6V at IDWeek 2026

You may also like

Crypto prices